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Abstract: Two new cytochalasins, sclerotionigrin A (1) and B (2) were isolated together 
with the known proxiphomin (3) from the filamentous fungus Aspergillus sclerotioniger. 
The structures and relative stereochemistry of 1 and 2 were determined based on 
comparison with 3, and from extensive 1D and 2D NMR spectroscopic analysis, supported 
by high resolution mass spectrometry (HRMS). Compounds 2 and 3 displayed cytotoxic 
activity towards chronic lymphocytic leukemia cells in vitro, with 3 being the most active.  
Keywords: cytochalasins; apergilli; Apsergillus sclerotioniger; chronic lymphocytic leukemia 
 
1. Introduction 
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia among adults in the 
Western World. CLL is considered an incurable disease and today’s applied treatment strategies 
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primarily aim at prolonging patient survival [1,2]. Consequently discovery of compounds that act 
against CLL and other types of cancer cells is crucial. Numerous types of anticancer compounds have 
been reported in the literature [3,4], and with the increase in specific biological assays, both novel and 
previously described compounds might display promising novel bioactivities [5,6]. An important and 
diverse group of fungal anticancer compounds that have caught our interest due to their wide range of 
biological functions are the cytochalasans [7]. In particular this includes inhibitory activities towards 
lung, ovarian, and human colon cancer as well as human leukemia [8,9]. Recently, we have demonstrated 
that chaetoglobosin A, produced by Penicillium aquamarinum, selectively induces apoptosis in CLL 
cells with a median lethal concentration (LC50) value of 2.8 µM [10]. Encouraged by this finding we 
searched for potential novel cytochalasan type of compounds in black aspergilli.  
The only documented indication of production of cytochalasans in Aspergillus subgenus Circumdati 
section Nigri is aspergillin PZ, for which aspochalasin C or D has been suggested as precursor [11,12]. 
However in the sister clade Aspergillus subgenus Circumdati section Flavipedes, numerous 
cytochalasans have been reported [13–26] including aspochalasin A–D [27,28]. Also in another 
species of Aspergillus subgenus Circumdati section Circumdati, Aspergillus elegans several 
cytochalasins were found, including aspergillin PZ [29], supporting the view that aspochalasin D is a 
precursor of aspergillin PZ. Finally in the less closely related Aspergillus clavatus in Aspergillus 
subgenus Fumigati section Clavati, cytochalasin E and K have been isolated [30,31]. 
Here we report the target-guided isolation and structure elucidation based on UV, MS, and NMR data of 
the two novel cytochalasins sclerotionigrin A (1) and B (2). Compounds 1 and 2 were isolated from 
Aspergillus sclerotioniger (IBT 22905) together with the known cytochalasin proxiphomin (3) [32]. We 
have previously reported ochratoxin A, ochratoxin B and pyranonigrin A from this isolate [33]. 
2. Results and Discussion 
The structure of compound 3 (Figure 1) was tentatively identified through UHPLC-DAD-HRMS 
based dereplication of the crude extract. The pseudomolecular ion, [M+H]+, was recognized from the 
mass spectrum due to the presence of the sodiated adduct, [M+Na]+ and the corresponding dimeric 
adducts [2M+H]+ and [2M+Na]+. The molecular formula C29H37NO2 was established with an accuracy 
of 0.8 ppm through the monoisotopic mass of [M+H]+ of m/z 432.2901. The formula was used for a 
query in Antibase2012 [34] with one resulting hit, proxiphomin (3). NMR data and optical rotation of 
3 matched published data [32]. 
Figure 1. Structures of sclerotionigrin A (1), sclerotionigrin B (2) and proxiphomin (3). 
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Compound 1 was purified as a yellow powder. The UV spectrum displayed an absorption maximum  
at 210 nm. The ESI+ spectrum showed a distinct adduct pattern consisting of [M+H]+, [M+Na]+, 
[2M+H]+ and [2M+Na]+. The molecular formula C29H37NO3 (12 double-bond equivalents) was 
obtained from HRMS of [M+H]+ (m/z 448.2843) with an accuracy of 2.3 ppm. The 1H-NMR spectrum 
revealed the presence of one amide proton, 15 methines (five which were vinylic and five aromatic), 
six methylenes, and three methyls (Table 1). 
Table 1. NMR data for sclerotionigrin A (1) †. 
No. δH (Integral, Mult., J [Hz]) δC HMBC NOESY 
1 - 170.6 - - 
2 8.00 (1H, s) - 1, 3, 4, 9 3, 10 
3 3.09 (1H, td, 5.8, 3.1) 54.2 - 2, 4, 10, 11, 12, 26/30 
4 2.53 (1H, dd, 4.2, 3.1) 49.1 3, 5, 6, 9 3, 10, 11, 26/30 
5 2.57 (1H, m) 33.6 - 7, 8, 11 
6 - 140.0 - - 
7 5.25 (1H, m) 123.6 - 5, 8, 12 
8 3.15 (1H, m) 45.8 - 5, 7, 13, 14 
9 - 85.4 - - 
10 2.82 (2H, m) 42.6 3, 4, 25, 26/30 3, 4, 26/30 
11 0.68 (3H, d, 7.1) 12.8 4, 5, 6 3, 4, 5, 12, 26/30 
12 1.65 (3H, s) 19.4 5, 6, 7 3, 7, 11 
13 5.85 (1H, ddd, 14.8, 10.0, 1.2) 128.9 15 8, 15 
14 5.22 (1H, m) 132.6 8 8, 15', 16 
15 1.60 (1H, d, 13.5) 40.7 13, 14, 16 13, 15' 
15' 2.07 (1H, dd, 13.5, 2.1) 40.7 - 14, 15, 16, 20', 24 
16 1.36 (1H, m) 31.9 - 14, 15', 19' 
17 0.61 (1H, m) 33.8 - 17', 18', 24 
17' 1.66 (1H, m) 33.8 - 17 
18 1.14 (1H, m) 25.9 - 18' 
18' 1.53 (1H, m) 25.9 - 17, 18 
19 1.29 (1H, m) 25.3 - 24 
19' 1.68 (1H, m) 25.3 - 16, 21 
20 2.23 (1H, m) 33.1 - 20', 21 
20' 2.29 (1H, m) 33.1 - 15', 20, 22 
21 6.96 (1H, ddd, 15.5, 8.6, 6.8) 151.7 23 19', 20, 22 
22 5.65 (1H, d, 15.5) 120.6 20, 23 20', 21 
23 - 163.5 - - 
24 0.84 (3H, d, 6.3) 20.0 15, 16, 17 15', 17, 19 
25 - 137.8 - - 
26 ‡ 7.14 (1H, app. d, 7.5) 129.5 10, 26/30, 28 3, 4, 10, 11 
27 ‡ 7.26 (1H, app. t, 7.4) 128.0 25, 29 - 
28 7.18 (1H, app. t, 7.5) 126.1 26, 30 - 
29 ‡ 7.26 (1H, app. t, 7.5) 128.0 25, 27 - 
30 ‡ 7.14 (1H, app. d, 7.5) 129.5 10, 26/30, 28 3, 4, 10, 11 
† 1H NMR data were obtained at 500 MHz in DMSO-d6 and 13C data were obtained at 125 MHz in DMSO-d6. 
13C-NMR chemical shifts were determined from HSQC and HMBC experiments; ‡ It was not possible to 
distinguish between No. 26 and 30 as well as No. 27 and 29. 
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The DQF-COSY spectrum of 1 defined four spin systems. The linking between COSY spin systems 
and assignments of the remaining signals and quaternary carbons were accomplished through detailed 
analysis of HMBC experimental data (Figure 2). 
Figure 2. Important HMBC correlations connecting the four COSY spin systems (marked 
in bold) in 1. The remaining HMBC correlations are found in Table 1. 
1 
The HMBC correlations from the protons at δH 2.82 ppm (H10) and 7.26 (H27 and H29) to a 
quaternary carbon at δC 137.8 (C25), together with HMBC correlations from the protons at δH 7.14 
(H26 and H30) to the carbon at δC 42.6 (C10) linked two of the spin systems belonging to the Phe 
moiety in 1. The amide proton at δH 8.00 ppm (H2) displayed HMBC correlations to the carbons  
at δC 54.2 (C3) and 170.6 ppm (C1). Combination of these HMBC correlations established the Phe 
moiety of 1, which was incorporated on the polyketide (PK) part of the molecule. 
The PK part of 1 could be established through a large COSY spin system (from H7 to H22), equal 
to that seen in 3. Furthermore a COSY coupling was found between the proton at δH 2.57 ppm (H5) 
and a methyl group at 0.68 ppm (H11). This part was coupled to the PK part by a weak COSY 
coupling between H5 and H7 identified as a 4J alyllic coupling. The COSY spin system could 
furthermore be connected via HMBC correlations to the above mentioned Phe moiety as well as the 
PK part. The protons at δH 1.65 (H12) correlated to the carbons at δC 33.6 (C5) and 123.6 ppm (C7) 
where the proton at δH 0.68 (H11) correlated to the carbons at δC 49.1 (C4) and 140.0 ppm (C6). The 
proton at 2.53 ppm (H4) correlated to C5, C6 and the quaternary carbon at δC 85.4 ppm (C9). Finally 
the PK chain was closed via an ester bond assigned from HMBC correlations from the vinylic protons 
at δH 5.65 (H22) and 6.96 ppm (H21) to the carbonyl carbon at δC 163.5 ppm (C23) supported by the 
high chemical shift of the quaternary carbon at δC 85.4 ppm (C9) indicating that C9 is bound to 
oxygen, and a carbonyl group, similar to what is seen in several other cytochalasans [7].  
This structure accounted for all the degree of unsaturation required by the formula allowing the 
assignment of 1 as sclerotionigrin A. The size of the vicinal coupling constants (3JHH) for H13/H14 and 
H21/H22 were rather large (14.8 and 15.5 Hz respectively) suggesting a trans stereochemistry. 
NOESY experiments enabled determination of the relative stereochemistry for most of the stereogenic 
centers of 1. NOE connectivities were found between the proton at δH 3.09 ppm (H3), δH 2.53 (H4) and 
the methyl at δH 0.68 ppm (H11) placing these protons at the same side of the central ring system, 
which to the best of our knowledge has not been reported for other cytachalasins. Other NOE 
connectivities were observed between the protons at δH 2.57 ppm (H5), 5.25 (H7) and 3.15 (H8), 
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whereas no NOE connectivities could be seen from either of these to H3, H4 or H11, strongly 
indicating the positioning of H5, H7 and H8 on the opposite side of the central ring system  
compared to H3, H4 and H11. The stereocenters at C9 and C16 could not be assigned through  
NOESY connectivities; however being biosynthesized by the same fungus we propose that the 
stereochemistries at these centers are identical to those of 3. Especially we note that the extra oxidation 
between C9 and C23 in other cytochalasans never leads to a change in stereochemistry at C9 [7,15]. 
We do however note that the optical rotation of 1 and 2 are positive as opposed to that of 3 and other 
similar cytochalasans [15], indicating a possible difference in stereochemistry, which could be 
accounted for by the change of stereochemistry at C4. Further experiments, e.g., X-ray crystallography 
or circular dichroism (CD) are therefore needed to clarify the absolute stereochemistry of 1. 
Compound 2 was isolated as a yellow powder, and displayed a UV absorption maximum at 212 nm 
and the ESI+ MS adducts [M+H]+, [M+Na]+, [2M+H]+ and [2M+Na]+. The molecular formula of 2, 
C29H37NO4 was deduced from the monoisotopic mass obtained from the [M+H]+ ion (m/z 464.2797) 
with an accuracy of 1.2 ppm. Examination of the NMR spectra of 2 displayed a high similarity 
compared to 1. Comparison of the NMR spectra of 1 and 2 (see Tables 1 and 2, respectively) revealed 
that the difference between them is located in positions five, six and seven. The Phe moiety in 2 was 
identified through a connection of the two COSY spin systems linked by HMBC correlations as 
demonstrated for 1. The COSY spin system of the PK chain terminated with a proton at δH 3.68 ppm 
(H7), indicating a binding to a hydroxyl group instead of the vinylic methine group observed for 1 at 
this position. This was also evident from the carbon chemical shift moving to δC 69.1 ppm (C7). 
HMBC correlations from the three protons of the methyl group at δH 1.52 ppm (H12) to the  
carbons at δC 123.9 (C5), 134.2 (C6) and 69.1 (C7), combined with correlations from the protons at  
δH 1.16 ppm (H11) to the carbons at δC 47.1 (C4) and 123.9 ppm (C5) and 134.2 (C6) linked the Phe 
moiety to the spin system in the polyketide chain (Figure 3). The remaining chemical shifts in 2 
matched the chemical shifts of 1 (Tables 1 and 2) and the structure of 2 was established altogether 
giving a classic methylated cytochalasin carbon skeleton [7]. 
The relative stereochemistry of 2 was established partly through NOE connectivities (Table 2) and 
shown to be very similar to that of 1. Connectivities between H3 and H4 were however not confirmed 
in 2, since these resonances were overlapping with the water resonance (Supplementary Figure S10). 
The optical rotation of 2 was positive like the optical rotation of 1, also indicating that the two 
compounds have the same relative stereochemistry. The absolute stereochemistry of 2 has not yet been 
solved. 
Biological testing of the cytotoxicity of compounds 1–3 towards CLL cells in vitro was performed 
using a CellTiter-Glo® assay [10]. Compound 3 displayed the strongest effects, with estimated LC50 
values of ca. 48 µM whereas no effect was found towards healthy B-cells in concentrations <100 µM. 
Compounds 1 showed minor activity at a concentration of 72 µM, while 2 did not have any effect 
(Table 3 and Supplementary Table S2, Figures S17, S18), indicating that the novel stereochemistry in 
the central ring system of 1 and 2 has a negative effect on target interactions. Due to the low anticancer 
activities of the sclerotionigrins, no further investigations proving their exact mode of action  
were undertaken. 
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Table 2. NMR data for sclerotionigrin B (2) †. 
No. δH (Integral, Mult., J [Hz]) δC  HMBC NOESY 
1 - 171.2 - - 
2 8.34 (1H, br. s) - 3, 4, 9 3, 10' 
3 3.39 (1H, m) 57.7 1, 4, 5, 9 2, 10, 10', 11, 26/30 
4 3.32 (1H, m) 47.1 1, 5, 6, 9 13, 26/30 
5 - 123.9 - - 
6 - 134.2 - - 
7 3.68 (1H, d, 9.7) 69.1 - 8, 12, 13 
8 3.05 (1H, t, 10.0) 48.3 1, 4, 7, 9, 13, 14 7, 13, 14 
9 - 83.6 - - 
10 2.55 (1H, dd, 13.0, 10.1) 42.5 3, 4, 25, 26/30 3, 10', 26/30 
10' 2.92 (1H, dd, 13.0, 5.0) 42.5 3, 4, 25, 26/30 2, 3, 10, 26/30 
11 1.16 (3H, s) 16.7 4, 5, 6 3, 26/30 
12 1.52 (3H, s) 14.3 5, 6, 7 7 
13 6.03 (1H, dd, 15.0, 11.3) 128.4 8, 15/15’ 4, 7, 8, 14, 15 
14 5.00 (1H, ddd, 15.0, 10.8, 3.4) 132.7 8, 15/15’ 8, 13, 15, 15' 
15 1.58 (1H, dt, 13.0, 11.1) 41.6 16 13, 14, 15', 16, 17' 
15' 2.00 (1H, m) 41.6 - 14, 15, 16, 24 
16 1.13 (1H, m) 32.5 - 15, 15', 17', 18, 24 
17 0.52 (1H, m) 34.5 - 17' 
17' 1.67 (1H, m) 34.5 24 15, 16, 17, 18, 24 
18 0.86 (1H, m) 26.1 - 16, 17', 18' 
18' 1.68 (1H, m) 26.1 20 18, 19, 21 
19 1.30 (1H, m) 25.4 - 18', 19' 
19' 1.73 (1H, m) 25.4 - 19 
20 2.11 (1H, m) 33.4 - 20', 22 
20' 2.41 (1H, m) 33.4 - 20, 21 
21 6.89 (1H, ddd, 15.7, 10.8, 5.0) 151.4 20, 23 18', 20', 22 
22 5.79 (1H, d, 16.1) 121.3 20, 23 20, 21 
23 - 163.8 - - 
24 0.83 (3H, d, 6.6) 19.9 15, 16, 17 15', 16, 17' 
25 - 137.4 - - 
26 ‡ 7.08 (1H, app. d, 7.1) 128.9 10, 28, 30 3, 4, 10, 10', 11, 27/29
27 ‡ 7.31 (1H, app. t, 7.5) 128.2 25, 29 26/30, 28 
28 7.23 (1H, app. t, 7.4) 126.3 26, 30 27/29 
29 ‡ 7.31(1H, app. t, 7.5) 128.2 25, 27 26/30, 28 
30 ‡ 7.08 (1H, app. d, 7.1) 128.9 10, 26, 28 3, 4, 10, 10',11, 27/29 
† 1H-NMR data were obtained at 500 MHz in DMSO-d6 and 13C data were obtained at 125 MHz in DMSO-
d6. 13C-NMR chemical shifts were determined from HSQC and HMBC experiments; ‡It was not possible to 
distinguish between no. 26 and 30 as well as no. 27 and 29. The hydroxyl group at C7 is not observed, 
presumable because it overlaps with the water resonance. 
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Figure 3. Important HMBC correlations establishing the quaternary carbon C5 and C6  
in 2. The remaining HMBC correlations are found in Table 2. Individual COSY spin 
systems are marked in bold. 
 2 
Table 3. Estimated LC50 values for compound 1–3. 
Compound CLL Healthy B-Cells
Sclerotionigrin A (1) 72 µM No effect 
Sclerotionigrin B (2) No effect No effect 
Proxiphomin (3) 48 µM No effect 
3. Experimental Section  
3.1. Fungal Growth and Extraction 
Aspergillus sclerotioniger (IBT 22905 = CBS 115572) is from the IBT culture collection at 
Department of Systems Biology, Technical University of Denmark. A. sclerotioniger was inoculated as 
three point inoculations on Czapek yeast agar (CYA) on 100 plates at 25 °C for 7 days in the dark. 
CYA plates were prepared as described by Samson et al. [35]. The plates were harvested and extracted 
twice overnight with ethyl acetate (EtOAc) containing 1% formic acid (FA). The extracts were filtered 
and concentrated in vacuo. Work up: The combined extract was dissolved in methanol (MeOH)/ 
milliQ-water (water purified and deionized by a Millipore system through 0.22 μm membrane filter) 
(9:1) and an equal amount of heptane was added followed by separation of phases. Additional  
milliQ-water was added to the MeOH/water phase until a ratio of 1:1 was reached, and metabolites 
were extracted with dichloromethane (DCM). The phases were then concentrated separately in vacuo. 
The DCM phase was used for further fractionation.  
3.2. Preparative Isolation of Cytochalasins 
The extract was dry-loaded on diol resin and fractionated on a 50 g pre-packed diol column using 
an Isolera One automated flash purification system (Biotage, Uppsala, Sweden). The compounds were 
eluted using a seven step gradient of heptane-DCM-EtOAc-MeOH with a flow rate of 40 mL/min. 
Fractions were collected automatically (1 column volume in each fraction). The Isolera fractions were 
subjected to further purification on a semi-preparative HPLC Waters 600 Controller with a 996 
photodiode array detector (Waters, Milford, MA, USA) on a Luna II C18 column 250 × 10 mm, 5 μm 
(Phenomenex, Torrance, CA, USA). A flowrate of 5 mL/min was used and 50% acetonitrile (ACN) 
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isocratic for 5 min, then to 100% in 15 min. 50 ppm trifluoroacetic acid (TFA) was added to ACN and 
milliQ-water. This yielded 1 (7.8 mg), 2 (2.1 mg), and 3 (1.3 mg). 
Sclerotionigrin A (1) Yellow solid; [α]589.3nm: +4° (c 0.8, MeOH); UV (ACN) λmax: 210 nm; HRMS 
m/z 448.2843 ([M + H]+ calculated for C29H38NO3, m/z 448.2853; 2.3 ppm); 13C- and 1H-NMR:  
see Table 1. 
Sclerotionigrin B (2) Yellow solid; [α]589.3nm: +41° (c 0.2, MeOH); UV (ACN) λmax: 212 nm; HRMS m/z 
464.2797 ([M + M]+ calculated for C29H38NO4, m/z 463.2724; 1.2 ppm); 13C- and 1H-NMR: see Table 2. 
Proxiphomin (3) Yellow solid; [α]589.3nm: −21° (c 0.1, MeOH); UV (ACN) λmax: 244 nm; HRMS m/z 
432.2901 ([M + H]+ calculated for C29H38NO2, m/z 432.2904; 0.8 ppm); 1H-NMR (DMSO-d6, 500 MHz): 
δ 0.77 (3H, d, 7.2, H11), 0.85 (3H, d, 6.7, H24), 1.13 (2H, m, H18), 1.23 (2H, m, H17), 1.38 (1H, m, 
H16), 1.41 (1H, m, H19), 1.56 (1H, m, H19'), 1.66 (3H, s, H12), 1.67 (1H, m, H15), 1.99 (1H, m,, 
H15'), 2.02 (1H, m, H20), 2.20 (1H, m, H5), 2.28 (1H, m, H20'), 2.40 (1H, dd, 13.2, 7.3, H10), 2.60 
(1H, dd, 13.2, 4.9, H10'), 2.63 (1H, m, H8), 2.80 (1H, dd, 5.8, 2.6, H4), 3.25 (1H, m, H3), 5.11 (1H, 
ddd, 14.6, 10.3, 3.2, H14), 5.27 (1H, m, H7), 6.18 (1H, ddd, 15.2, 9.8, 1.7, H13), 6.54 (1H, ddd, 15.4, 
10.2, 5.3, H21), 6.86 (1H, d, 15.5, H22), 7.10 (1H, d, 7.5, H26), 7.10 (1H, d, 7.5, H30), 7.16 (1H, d, 
7.5, H28), 7.25 (1H, dd, 7.4, 1.0, H27), 7.25 (1H, dd, 7.4, 1.0, H29), 7.94 (1H, s, H2). 13C-NMR 
(DMSO-d6, 125 MHz) δ 12.6 (C11), 19.3 (C12), 20.8 (C24), 23.1 (C18), 25.2 (C19), 28.5 (C17), 31.1 
(C20), 31.9 (C16), 33.7 (C5), 39.7 (C15), 43.1 (C10), 47.0 (C8), 47.2 (C4), 53.0 (C3), 65.7 (C9), 125.8 
(C7), 126.0 (C28), 127.3 (C22), 127.9 (C27), 127.9 (C29), 129.3 (C13), 129.5 (C26), 129.5 (C30), 
131.6 (C14), 136.7 (C25), 139.1 (C6), 145.7 (C21), 173.6 (C1), 196.9 (C23). 
3.3. Chemical Analysis 
Analysis of extracts was performed using ultra-high-performance liquid chromatography (UHPLC) 
UV/Vis diode array detector (DAD) high-resolution MS on a maXis 3G orthogonal acceleration 
quadrupole time of flight mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped with an 
electrospray ionization (ESI) source and connected to an Ultimate 3000 UHPLC system (Dionex, 
Sunnyvale, CA, USA). The mass spectrometer was calibrated using sodium formate automatically 
infused prior to each analytical run, providing a mass accuracy below 1 ppm. Separation was achieved 
on a Kinetex C18, 2.6 µm, 2.1 × 100 mm column (Phenomenex) with a flow rate of 0.4 mL·min−1 at 40 °C 
using a linear gradient 10% ACN in milliQ water going to 100% ACN in 10 min. Both solvents were 
buffered with 20 mM formic acid. 
3.4. NMR and Optical Roation 
One-dimensional and two-dimensional NMR experiments were acquired on a 500 MHz Varian 
Unity Inova (Palo Alto, CA, USA) equipped with a HCP probe. 1H, DQF-COSY, edHSQC, HMBC 
and NOESY experiments were acquired using standard pulse sequences. Optical rotation values were 
obtained on a Perkin-Elmer 241 Polarimeter at 589 nm. 
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3.5. CLL Cells, Cell Viability and Apoptosis Assays 
Whole blood samples were obtained from healthy donors or patients that matched the standard 
diagnostic criteria for CLL after informed consent in accordance with the Declaration of Helsinki.  
All studies performed were approved by the ethics committee of the University of Ulm. Peripheral 
blood B cells were isolated by Ficoll density gradient followed by magnetic cell enrichment using 
CD19-MACS beads (Miltenyi Biotech, Bergisch Gladbach, Germany). Healthy donor B cells or CLL 
cells were cultured in conditioned medium of HS-5 cells, which was harvested after 3–4 days of 
culture and 80% confluency and depleted of HS-5 cells and debris by centrifugation. Cells were seeded 
in duplicates at a density of 3 × 105 cells/well in opaque-walled 96-well plates. Pure compounds were 
added in different concentrations and incubated for 24 h. A final concentration of 0.1% DMSO was 
used as negative control and 100 µM fludarabine as positive control. Cell viability was assessed using 
CellTiter-Glo® assay (Promega, Madison, WI, USA) according to manufacturer’s protocol. Luminescence 
signals were recorded using a Mithras LB940 plate reader (Berthold Technologies, Bad Wildbad, 
Germany). Relative cell viability was calculated as described by Knudsen et al. [10]. All compounds were 
tested on the same patient cells under the same conditions. For patient data, see Supplementary  
Table S2, Figures S17, S18. 
4. Conclusions  
In summary the two new cytochalasins, sclerotionigrin A (1) and B (2) have been isolated from A. 
sclerotioniger, together with the known proxiphomin (3). Compound 3 displayed the strongest 
cytotoxic effects towards CLL, however not as promising as recently demonstrated for chaetoglobosin 
A [10]. This is the first report of cytochalasan production from one of the currently more than twenty-
five known black Aspergillus species [36,37], even though cytochalasans are very common in the 
related yellow Aspergillus species such as A. flavipes, A. terreus and A. elegans [29,38]. Further 
species in Aspergillus section Nigri should be examined for cytochalasan production, as the 
cytochalasan related metabolite, aspergillin PZ, has also been found in this group in addition to 
proxiphomin, and sclerotionigrin A and B. This may be important for both drug discovery and food 
safety, as the black Aspergilli are common in foods. 
Supplementary Materials 
1H, DQF-COSY, HSQC, HMBC and NOESY spectra for all three compounds, as well as bioassay 
results are available in the supporting information. Supplementary materials can be accessed at: 
http://www.mdpi.com/1420-3049/19/7/9786/s1. 
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